These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 27624686)

  • 1. Modulation of sphingosine receptors influences circadian pattern of cardiac autonomic regulation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Physiol Rep; 2016 Sep; 4(17):. PubMed ID: 27624686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen P; Hartikainen JE
    Mult Scler; 2016 Jul; 22(8):1080-5. PubMed ID: 26362903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac repolarization during fingolimod treatment in patients with relapsing-remitting multiple sclerosis.
    Laiho A; Laitinen TM; Hartikainen P; Hartikainen JEK; Laitinen TP; Simula S
    Brain Behav; 2018 Feb; 8(2):e00925. PubMed ID: 29484274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence of cardiovascular autonomic alterations after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JEK
    Ann Noninvasive Electrocardiol; 2017 Sep; 22(5):. PubMed ID: 28191684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart rate variability predicts the magnitude of heart rate decrease after fingolimod initiation.
    Simula S; Laitinen TP; Laitinen TM; Hartikainen P; Hartikainen JE
    Mult Scler Relat Disord; 2016 Nov; 10():86-89. PubMed ID: 27919506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The autonomic balance predicts cardiac responses after the first dose of fingolimod.
    Rossi S; Rocchi C; Studer V; Motta C; Lauretti B; Germani G; Macchiarulo G; Marfia GA; Centonze D
    Mult Scler; 2015 Feb; 21(2):206-16. PubMed ID: 24957049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Three Months Fingolimod Therapy on Heart Rate.
    Simula S; Laitinen T; Laitinen TM; Tarkiainen T; Hartikainen JE; Hartikainen P
    J Neuroimmune Pharmacol; 2015 Dec; 10(4):651-4. PubMed ID: 26092537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing.
    Hilz MJ; Intravooth T; Moeller S; Wang R; Lee DH; Koehn J; Linker RA
    PLoS One; 2015; 10(7):e0132139. PubMed ID: 26147106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The analysis of circadian rhythm of heart rate variability in patients with drug-resistant epilepsy.
    Yang Z; Liu H; Meng F; Guan Y; Zhao M; Qu W; Hao H; Luan G; Zhang J; Li L
    Epilepsy Res; 2018 Oct; 146():151-159. PubMed ID: 30165244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate variability decreases after 3 months of sustained treatment with fingolimod.
    Vehoff J; Haegele-Link S; Humm A; Kaegi G; Mueller SK; Sauter R; Tettenborn BE; Hundsberger T
    J Neurol; 2017 Nov; 264(11):2313-2317. PubMed ID: 28993873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis.
    Akbulak RÖ; Rosenkranz SC; Schaeffer BN; Pinnschmidt HO; Willems S; Heesen C; Hoffmann BA
    Mult Scler Relat Disord; 2018 Jan; 19():44-49. PubMed ID: 29127856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian profile of cardiac autonomic nervous modulation in healthy subjects: differing effects of aging and gender on heart rate variability.
    Bonnemeier H; Richardt G; Potratz J; Wiegand UK; Brandes A; Kluge N; Katus HA
    J Cardiovasc Electrophysiol; 2003 Aug; 14(8):791-9. PubMed ID: 12890036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circadian heart rate variability in patients with primary arterial hypertension.
    Kolasińska-Kloch W; Furgała A; Banach T; Laskiewicz J; Thor PJ
    Przegl Lek; 2002; 59(9):752-5. PubMed ID: 12632903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?
    Kocyigit D; Yalcin MU; Gurses KM; Tokgozoglu L; Karabudak R
    Mult Scler Relat Disord; 2019 Jan; 27():276-280. PubMed ID: 30447536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod.
    Vanoli E; Montano N; De Angelis G; Badilini F; Mirabella M; Bonavita S; Patti F; Bianco A; Sparaco M; Chisari C; Laroni A; Frigerio F; Bartezaghi M; Rossi S; Turrini R; Mancardi G
    J Neurol Sci; 2019 Oct; 405():116423. PubMed ID: 31520869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vagomimetic effects of fingolimod: physiology and clinical implications.
    Vanoli E; Pentimalli F; Botto G
    CNS Neurosci Ther; 2014 Jun; 20(6):496-502. PubMed ID: 24836740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
    Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
    Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis.
    Montalban X; Comi G; Antel J; O'Connor P; de Vera A; Cremer M; Sfikas N; von Rosenstiel P; Kappos L
    J Neurol; 2015 Dec; 262(12):2627-34. PubMed ID: 26338810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).
    Meissner A; Limmroth V
    Mult Scler Relat Disord; 2016 Jul; 8():19-26. PubMed ID: 27456870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 6-Month Effects of Fingolimod on Indexes of Cardiovascular Autonomic Control in Multiple Sclerosis.
    Racca V; Rovaris M; Vaini E; Cavarretta R; Ferratini M; Toccafondi A; Di Rienzo M
    J Am Coll Cardiol; 2016 Nov; 68(18):2027-2029. PubMed ID: 27788858
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.